On April 12, 2024, AEON Biopharma, Inc. closed the transaction. The company issued one senior secured convertible note in the principal amount of $10,000,000 for a gross proceeds $10,000,000 in its final tranche. The Convertible Note contains customary events of default, accrues interest at an annual rate of 15.79% and has a maturity date of April 12, 2027, unless earlier repurchased, converted or redeemed in accordance with its terms prior to such date.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.69 USD | -15.08% | +6.96% | -76.53% |
May. 09 | AEON Biopharma, Inc. Provides Update on Development Pipeline | CI |
May. 03 | US Equity Markets Close Higher Friday Following Weak Jobs Report | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
108,400 KRW | -0.82% | -2.78% | 921M | ||
1.69 USD | -15.08% | +6.96% | 77.18M | ||
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-76.53% | 77.18M | |
+10.79% | 115B | |
+11.65% | 106B | |
-6.20% | 24.69B | |
-2.33% | 21.97B | |
-6.03% | 19.27B | |
-13.41% | 17.56B | |
-40.50% | 17.32B | |
+6.64% | 14.03B | |
+31.84% | 12.13B |
- Stock Market
- Equities
- AEON Stock
- News AEON Biopharma, Inc.
- AEON Biopharma, Inc. announced that it has received $15 million in funding from Daewoong Pharmaceutical Co., Ltd